Information Provided By: 
Fly News Breaks for November 12, 2019
RETA
Nov 12, 2019 | 06:15 EDT
Citi analyst Yigal Nochomovitz raised his price target for Reata Pharmaceuticals to $328 from $241 saying last night's Phase 3 bardoxolone data "hits it out of the park." The stock in premarket trading is down 8%, or $16.67, to $197.00. This data will be "more than sufficient" for Reata to obtain accelerated approval, Nochomovitz tells investors in a research note. He keeps a Buy rating on Reata Pharmaceuticals.
News For RETA From the Last 2 Days
There are no results for your query RETA
